Search research articles
Contact Us
Filters
Showing results (101-110 of 272) with videos related to
Page
of 28
Sort By:
International Journal of Cancer
|
November 21, 2022
Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations
Rémi Longuespée, Dirk Theile, Inka Zörnig, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 15, 2023
Can physiologic colonic [<sup>18</sup>F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
Christos Sachpekidis, Christoph K Stein-Thoeringer, Annette Kopp-Schneider, et al.
Trends in Immunology
|
December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicities
Robin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Oncoimmunology
|
May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case series
Jessica C Hassel, Sophia B Lee, Frank Meiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2021
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
Martin Salzmann, Georgi Tosev, Melanie Heck, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients
Sophia B Strobel, Devayani Machiraju, Melanie Wiecken, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 8, 2012
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers
Bernhard Homey, Peter Arne Gerber, Andreas Wollenberg, et al.
Current Oncology (Toronto, Ont.)
|
April 27, 2026
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events
Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, et al.
Page
of 28
Search research articles
Search
Showing results (101-110 of 272) with videos related to
Sort By:
Page
of 28
International Journal of Cancer
|
November 21, 2022
Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations
Rémi Longuespée, Dirk Theile, Inka Zörnig, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 15, 2023
Can physiologic colonic [<sup>18</sup>F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?
Christos Sachpekidis, Christoph K Stein-Thoeringer, Annette Kopp-Schneider, et al.
Trends in Immunology
|
December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicities
Robin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 5, 2016
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Katharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Oncoimmunology
|
May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case series
Jessica C Hassel, Sophia B Lee, Frank Meiss, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2021
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
Martin Salzmann, Georgi Tosev, Melanie Heck, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients
Sophia B Strobel, Devayani Machiraju, Melanie Wiecken, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 8, 2012
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers
Bernhard Homey, Peter Arne Gerber, Andreas Wollenberg, et al.
Current Oncology (Toronto, Ont.)
|
April 27, 2026
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events
Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, et al.
Page
of 28